Adamas Pharmaceuticals Inc Form 3 July 06, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION **OMB APPROVAL** FORM 3 Washington, D.C. 20549 OMB Number:

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> MERRIWEATHER ALFRED G			2. Date of Event Requiring Statement (Month/Day/Year) 06/29/2017	3. Issuer Name and Ticker or Trading Symbol Adamas Pharmaceuticals Inc [ADMS]		
(Last)	(First)	(Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)	
C/O ADAMAS				(Check all applicable)	Thed (Month Day) Tear)	
PHARMACEUTICALS, INC., 1900 POWELL ST.,				(Check an applicable)		
SUITE 750		201.,		Director 10% Owner		
(Street)				XOfficerOther (give title below) (specify below) Chief Financial Officer	6. Individual or Joint/Group Filing(Check Applicable Line)	
					X Form filed by One Reporting	

EMERYVILLE, CAÂ 94608

(City)	(State)	(Zip)	Table I - Non-Derivat	ive Securiti	es Beneficially Owned
1.Title of Securi (Instr. 4)	ity		2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities	benefically	owned	0	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership

3235-0104

January 31,

2005

0.5

Expires:

response...

Person

Reporting Person

Form filed by More than One

Estimated average burden hours per

Edgar Filing: Adamas Pharmaceuticals Inc - Form 3

(Month/Day/Year)		Derivative Security (Instr. 4)		or Exercise Price of	Form of (Instr. 5) Derivative	(Instr. 5)
Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	

Reporting Owners

Reporting Owner Name / Address		Relationships						
I gent and a second		Director	10% Owner	Officer	Other			
MERRIWEATHER ALFRED G C/O ADAMAS PHARMACEUTICALS 1900 POWELL ST., SUITE 750 EMERYVILLE, CA 94608	S, INC.	Â	Â	Chief Financial Officer	Â			
Signatures								
/s/ Jennifer Rhodes, Attorney-in-fact	07/06/2	017						
**Signature of Reporting Person	Date							
Explanation of Respon	Explanation of Responses:							

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.